Large language models such as ChaptGPT have proven to be able to produce remarkably intelligent results, but the energy and monetary costs associated with running these massive algorithms is sky high.

Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...